FHCR-1-2813/FDC-6細(xì)胞

數(shù)量： 大量

運(yùn)輸方式： 凍存運(yùn)輸

細(xì)胞形態(tài)： **樣

**類型： IgG1

生長(zhǎng)狀態(tài)： 懸浮生長(zhǎng)

ATCC Number： HB-9018?

是否是腫瘤細(xì)胞： 0

物種來源： 小鼠

Designations: FHCR-1-2813/FDC-6

Depositors: Fred Hutchinson Cancer Res. Cntr.

Isotype: IgG1

Biosafety Level: 1

FHCR-1-2813/FDC-6細(xì)胞Shipped: frozen

Medium & Serum: See Propagation

Growth Properties: suspension

Organism: Mus musculus (B cell); Mus musculus (myeloma) deposited as mouse (B cell); mouse (myeloma)

Morphology: lymphoblast

Source: Cell Type: hybridoma: B lymphocyte;

Cellular Products: immunoglobulin; monoclonal antibody; against an onco-fetal determinant on human fibronectin

Permits/Forms: In addition to the MTA mentioned above, other ATCC and/or regulatory permits may be required for the transfer of this ATCC material. Anyone purchasing ATCC material is ultimately responsible for obtaining the permits. Please click here for information regarding the specific requirements for shipment to your location.

Comments: Animals were immunized with fibronectin from HuH-6 human hepatoma cells.

Spleen cells were fused with SP-1 myeloma cells.

The antibody reacts with human fibronectin from fetal and neoplastic tissues, but not from normal human tissues or plasma.

Propagation: FHCR-1-2813/FDC-6細(xì)胞ATCC complete growth medium: RPMI 1640 medium with 2 mM L-glutamine adjusted to contain 1.5 g/L sodium bicarbonate, 4.5 g/L glucose, 10 mM HEPES, and 1.0 mM sodium pyruvate and supplemented with 0.05 mM 2-mercaptoethanol, 88%; fetal bovine serum, 12%

Temperature: 37.0°C

Subculturing: Medium Renewal: Every 2 to 3 days

Cultures can be maintained by addition or replacement of fresh medium. Start cultures at 2 X 10 exp5 cells/ml and maintain between 1 X 10 exp5 and 1 X 10 exp6 cells/ml.

Preservation: culture medium 95%; DMSO, 5%

Related Products: FHCR-1-2813/FDC-6細(xì)胞Recommended medium (without the additional supplements or serum described under ATCC Medium):ATCC 30-2001

recommended serum:ATCC 30-2020

References: 1801: Loridon-Rosa B, et al. Distribution of oncofetal fibronectin in human mammary tumors: Immunofluorescence study on histological sections. Cancer Res. 50: 1608-1612, 1990. PubMed: 2406016

1802: Matsuura H, Hakomori S. The oncofetal domain of fibronectin defined by monoclonal antibody FDC-6: Its presence in fibronectins from fetal and tumor tissues and its absence in those from normal ***** tissues and plasma. Proc. Natl. Acad. Sci. USA 82: 6517-6521, 1985. PubMed: 2995969

1803: Matsuura H, et al. The oncofetal structure of human fibronectin defined by monoclonal antibody FDC-6. Unique structural requirement for the antigenic specificity provided by a glycosylhexapeptide. J. Biol. Chem. 263: 3314-3322, 1988. PubMed: 2449438

4008: Matsuura H, Hakomori S. Monoclonal antibody defining oncofetal structure of fibronectin. US Patent 4,894,326 dated Jan 16 1990

23548: FHCR-1-2813/FDC-6細(xì)胞Matsuura H, et al. An alpha-N-acetylgalactosaminylation at the threonine residue of a defined peptide sequence creates the oncofetal peptide epitope in human fibronectin. J. Biol. Chem. 264: 10472-10476, 1989. PubMed: 2471705